A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2024 and March 31, 2023 is as follows (in thousands):


Three Months Ended March 31, 2024	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Location in Financial Statements	Derma Sciences		ACell		Surgical Innovations Associates (SIA), Inc.			Location in Financial Statements
Balance as of January 1, 2024	$	15,755		$	2,557	$	300		68,700
Change in fair value of contingent consideration liabilities	(83)		Research and development	39		—			500			Selling, general and administrative
Balance as of March 31, 2024	15,672			2,596		300			69,200

Short-Term	$	7,562		$	—	$	—		$	29,300		Accrued expenses and other current liabilities
Long-Term	8,110			2,596		300			39,900			Other liabilities
Total	15,672			2,596		300			69,200


Three Months Ended March 31, 2023	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Location in Financial Statements	Derma Sciences		ACell		Surgical Innovations Associates (SIA), Inc.		Location in Financial Statements
Balance as of January 1, 2023	$	12,895		$	230	$	3,700	$	57,607
Change in fair value of contingent consideration liabilities	3,299		Research and development	—		(2,200)		3,600		Selling, general and administrative
Balance as of March 31, 2023	$	16,194		$	230	$	1,500	$	61,207

Short-Term	$	4,388		$	—	$	—	$	12,500	Accrued expenses and other current liabilities
Long-Term	11,806			230		1,500		48,707		Other liabilities
Total	16,194			230		1,500		61,207